We had previously established DYRK2 as a direct HSF1 phosphorylating kinase and showed that DYRK2 inhibition leads to impediment of the cell cycle via accumulation of proapoptotic factors leading to tumour regression of multiple myeloma and TNBC in vivo. The gene discussed is HSF1; the disease is plasma cell myeloma.